ESME队列22,000例转移性乳腺癌当代结局分析(2008-2016)
全队列中位OS 39.5个月(95%CI 38.7-40.3),5年OS 33.8%;三亚型OS差异显著(p<0.0001),HR+/HER2-、HER2+与三阴性中位OS分别为43.3、50.1与14.8个月。
要点
- 全队列转移性乳腺癌中位OS 39.5个月,5年OS 33.8%。
- 三阴性亚型中位OS仅14.8个月,显著低于HR+/HER2-与HER2+亚型。
- 内脏转移、转移部位≥3个及转移无间期6-24个月与更差OS相关。
核心结论
- ESME是大型真实世界转移性乳腺癌队列,揭示各亚型间生存差异显著及高医疗需求情境。
主要发现
- 全队列中位OS为39.5个月(95%CI 38.7-40.3),5年OS为33.8%。
- HR+/HER2-亚型(n=13,656)中位OS为43.3个月(95%CI 42.5-44.5)。
- HER2+亚型(n=4,017)中位OS为50.1个月(95%CI 47.6-53.1)。
- 三阴性亚型(n=2,963)中位OS为14.8个月(95%CI 14.1-15.5),三组差异p<0.0001。
- 全队列及亚型中,转移时年龄较大(三阴性除外)、转移无间期6-24个月、内脏转移、转移部位≥3个与OS负相关。
临床怎么用
- 可依据亚型、转移部位数量、内脏转移及转移无间期对转移性乳腺癌患者进行预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Real-world data inform the outcome comparisons and help the development of new therapeutic strategies. To this end, we aimed to describe the full characteristics and outcomes in the Epidemiological Strategy and Medical Economics (ESME) cohort, a large national contemporary observational database of patients with metastatic breast cancer (MBC). METHODS: Women aged ≥18 years with newly diagnosed MBC and who initiated MBC treatment between January 2008 and December 2016 in one of the 18 French Comprehensive Cancer Centers (N = 22,109) were included. We assessed the full patients' characteristics, first-line treatments, overall survival (OS) and first-line progression-free survival, as well as updated prognostic factors in the whole cohort and among the 3 major subtypes: hormone receptor positive and HER2-negative (HR+/HER2-, n = 13,656), HER2-positive (HER2+, n = 4017) and triple-negative (n = 2963) tumours. RESULTS: The median OS of the whole cohort was 39.5 months (95% confidence interval [CI], 38.7-40.3). Five-year OS was 33.8%. OS differed significantly between the 3 subtypes (p < 0.0001) with a median OS of 43.3 (95% CI, 42.5-44.5) in HR+/HER2-; 50.1 (95% CI, 47.6-53.1) in HER2+; and 14.8 months (95% CI, 14.1-15.5) in triple-negative subgroups, respectively. Beyond performance status, the following variables had a constant significant negative prognostic impact on OS in the whole cohort and among subtypes: older age at diagnosis of metastases (except for the triple-negative subtype), metastasis-free interval between 6 and 24 months, presence of visceral metastases and number of metastatic sites ≥ 3. CONCLUSIONS: The ESME program represents a unique large-scale real-life cohort on MBC. This study highlights important situations of high medical need within MBC patients. DATABASE REGISTRATION: clinicaltrials.gov Identifier NCT032753.
引用
- Deluche E, Antoine A, Bachelot T, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. Eur J Cancer. 2020. PMID: 32135312. doi:10.1016/j.ejca.2020.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。